---
document_type: gtm_research_ledger
title: Measures Registry GTM Research Ledger
status: git_formed_pending_operator_review
version: v1
timestamp: 2026-08-21
operator: op044
author: chazz
system: measures_registry
scope: go_to_market_research_and_market_validation
authoritative_custody: git
repository: c3codex/c3-Field
branch: gtm-ledger-v1
registry_standing: unregistered_pending_operator_disposition
source_authority_index: project_source_authority_index_v7.meta.md
source_concordance: source_concordance_current_v8.meta.md
operational_concordance: c3_operational_concordance_v3.meta.md
map_terminology_standing: held_unresolved
---

# Measures Registry GTM Research Ledger

## Purpose

Maintain a durable, evidence-led record of Measures Registry go-to-market research so market conclusions, ICP choices, buyer findings, offer decisions, acquisition experiments, counterevidence, and Operator dispositions accumulate without being mistaken for authority merely because research exists.

This ledger is a market-research and decision-evidence artifact. It does not by itself register a market position, authorize publication, establish a compliance claim, activate a sales campaign, resolve MAP terminology, or substitute research for observed buying behavior.

## Governing Research Principle

Research must answer a decision Measures Registry actually needs to make.

A persuasive report is not passage evidence by itself. Findings advance only when the evidence required by the applicable GTM gate is sufficient and the Operator disposes the finding.

The governing sequence is:

`MARKET → ICP → BUYER → OFFER → ACQUISITION`

Evidence may move backward when later findings challenge an earlier assumption.

## Five GTM Gates

| Gate | Decision | Governing question | Passage evidence |
| --- | --- | --- | --- |
| G1 Market | Select or reject a candidate market | Is there observable demand worth pursuing? | purchasing behavior, forcing events, accessibility, alternatives, ability to pay, counterevidence |
| G2 ICP | Define the organizations most likely to buy | Which organizations exhibit the conditions associated with demand? | organization type, scale, AI deployment, governance maturity, external trigger, internal ownership |
| G3 Buyer | Identify the people who experience, own, fund, or block the work | Who feels the problem, owns the work, approves spending, and influences procurement? | recent-behavior interviews, role evidence, procurement path, budget authority, blockers |
| G4 Offer | Define what the buyer will purchase | What bounded outcome, deliverable, price, and credibility package will the buyer accept? | buyer language, purchasing evidence, offer tests, price evidence, objections, conversion behavior |
| G5 Acquisition | Establish a repeatable path to qualified demand | Can Measures Registry reliably reach and convert the buyer? | qualified target cohort, channel response, assessment visits/starts/completions, conversations, opportunities, revenue |

## Research Record Schema

Every material GTM finding should preserve:

1. `record_id`
2. `date`
3. `gate`
4. `candidate_market_or_segment`
5. `hypothesis`
6. `evidence`
7. `counterevidence`
8. `confidence`
9. `unresolved_gap`
10. `research_method`
11. `source`
12. `finding`
13. `decision_implication`
14. `standing`
15. `operator_disposition`

Recommended standing values:

- `candidate_under_validation`
- `supported_pending_market_validation`
- `supported`
- `contradicted`
- `held_for_evidence`
- `rejected`
- `operator_confirmed`

A research source may support a finding without receiving operative authority. Tool access, file presence, model memory, technical capability, and persuasive synthesis do not create GTM standing.

## Research Method Allocation

### Chazz / Measures Registry

Use for research architecture, source synthesis, evidence evaluation, ICP logic, prospect scoring, competitor synthesis, buyer-interview design, assessment mapping, messaging tests, and interpretation of results.

### Public Primary Sources

Prefer provider and regulator datasets, hospital and health-system publications, leadership pages, procurement materials, RFP/RFI artifacts, job postings, conference presentations, Joint Commission and CHAI material, government sources, litigation records, and actual service offerings.

### Deep-Research Tools and Trials

Reserve for fragmented or expensive research questions where synthesis across many sources materially reduces uncertainty: observed purchasing behavior, accreditation/readiness activity, RFP and contract archaeology, consulting service and pricing evidence, procurement barriers, competitive alternatives, and adversarial falsification.

### Contact and Lead Tools

Use after the ICP and named-account rationale exist. Lead databases are retrieval machinery, not market authority. Contact enrichment should be spent on evidence-qualified prospects rather than broad market lists.

### Human Validation

Use for buyer ownership, recent operational behavior, willingness to pay, purchasing path, credibility requirements, objections, and actual decision dynamics. No research synthesis substitutes for observed buyer behavior.

## Case 001 — U.S. Healthcare Providers

### Case Standing

`candidate_under_validation`

Healthcare is the first candidate vertical entered into this ledger. Its inclusion records current research direction, not a final market disposition.

### G1 Market Hypothesis

Regional and community healthcare providers deploying AI may exhibit stronger near-term demand for independent computational-systems governance assessment than undifferentiated mid-market organizations.

The current thesis is driven more by accreditation/readiness and procurement behavior than by demonstrated regulatory enforcement.

### Primary Trigger Hypothesis

Joint Commission Responsible Use of AI in Healthcare (RUAIH) readiness may be the clearest provider-side forcing event because its governance expectations overlap with the environmental conditions Measures Registry already evaluates.

Standing:

`supported_pending_market_validation`

Required next evidence:

- adoption velocity outside flagship systems;
- hospitals publicly preparing for RUAIH;
- external readiness assistance being purchased;
- readiness timelines and budget ownership;
- evidence that RUAIH changes current behavior rather than merely signaling interest.

### Supporting Context Hypotheses

The following may strengthen the market context but are not presently treated as independent hard-demand triggers:

- Section 1557 §92.210 responsibilities;
- patient safety and quality governance;
- AI inventory and lifecycle oversight;
- hospital AI procurement and vendor-review requirements;
- state and federal payer rules where relevant to payer or utilization-review segments;
- litigation and enforcement precedent as credibility/context evidence.

### Current Counterevidence

The healthcare thesis must preserve the following weaknesses:

- RUAIH is voluntary rather than mandatory accreditation;
- published AI-specific enforcement remains limited;
- responsibility is distributed across committees;
- governance budgets may be thin or folded into existing IT, quality, safety, compliance, or privacy budgets;
- healthcare procurement may be slow or credential-heavy;
- malpractice underwriting has not clearly hardened around AI;
- payer litigation does not directly establish demand among community hospitals;
- evidence of health-tech deals actually lost because of missing AI-governance documentation remains thin.

### G2 ICP Hypothesis

Candidate organizations:

U.S. regional health systems and community hospitals large enough to operate meaningful clinical or administrative AI, but without mature dedicated responsible-AI governance infrastructure.

Variables to test:

- provider organization type;
- number of hospitals/facilities;
- employee count and operating scale;
- evidence of AI deployment;
- AI governance or responsible-AI activity;
- CHAI/RUAIH participation or readiness signals;
- clinical informatics leadership;
- quality/patient-safety leadership;
- compliance/privacy leadership;
- absence or presence of a dedicated AI governance office;
- procurement accessibility;
- geographic concentration.

A target account should be evidence-qualified before contact enrichment.

### G3 Buyer Hypothesis

Primary provider-side buying relation:

`CMIO / clinical informatics + Compliance + Quality / Patient Safety`

CIO/IT is expected to participate in many organizations but must not be presumed the economic buyer without evidence.

Research must distinguish:

- clinical champion;
- governance/process owner;
- compliance or quality owner;
- technical owner;
- economic approver;
- procurement gatekeeper;
- executive sponsor.

### Buyer Validation Method

Interview recent behavior rather than hypothetical interest.

Preferred prompts include:

- What happened the last time the organization introduced an AI system?
- Who had to review it before use?
- Where did the process slow down or fail?
- What documentation or evidence was requested?
- Has an external requirement changed that process?
- Has outside help been purchased?
- Who could approve that engagement and from what budget?

### G4 Offer Hypothesis

Candidate entrance:

`Healthcare AI Environment Assessment`

The assessment should remain a healthcare-context entrance into the existing Measures Registry measurement system rather than a separate compliance product.

Candidate passage:

`Healthcare AI Environment Assessment → findings → governed continuation where warranted`

A healthcare interpretation layer may crosswalk observed conditions to healthcare-specific readiness contexts without representing Measures Registry as a certification body, legal compliance auditor, or Joint Commission-authorized assessor.

Potential trigger frames to test without creating separate products:

1. responsible-AI / RUAIH readiness;
2. operational AI visibility and ownership;
3. procurement and governance evidence.

Buyer language and observed conversion should determine the preferred frame.

### G5 Acquisition Hypothesis

Initial acquisition should favor a small evidence-qualified cohort over a broad purchased list.

Candidate research cohort:

`25–50 provider organizations`

Preferred qualification sequence:

`provider fit → AI activity → governance/readiness signal → identifiable buyer → reachable contact`

Potential public-source spine:

`CMS / provider data → CHAI / readiness signals → hospital leadership and AI activity → NPPES identity context → contact discovery / verification`

The assessment may serve as both a market entrance and a measurable conversion surface.

Candidate acquisition measures:

`delivered → opened → assessment visited → assessment started → assessment completed → buyer conversation → MAP opportunity → revenue`

## Immediate Research Question

The first Gate 1 question is:

> Do regional U.S. healthcare providers exhibit observable purchasing behavior for outside AI-governance or responsible-AI readiness work, and what event causes that purchase to happen?

This question precedes broad lead generation.

## Priority Research Queue

1. RUAIH adoption and readiness behavior.
2. Actual hospital AI-governance consulting purchases, RFPs, RFIs, contracts, or readiness engagements.
3. Procurement requirements and barriers for outside governance/advisory work.
4. Competitive alternatives, including internal teams, CHAI resources, law firms, compliance consultants, EHR vendors, specialist consultancies, large advisory firms, and doing nothing.
5. A 25–50 account evidence-qualified provider cohort.
6. Buyer interviews across clinical informatics, quality/patient safety, compliance, IT, and procurement.
7. Offer and price evidence.
8. Acquisition experiments after G1–G3 evidence is sufficient.
9. Adversarial research attempting to falsify the healthcare thesis.

## Tool Trial Rule

Do not optimize research around whichever free trial or database happens to be available.

First define the decision and evidence gap. Then choose the least costly source or tool capable of producing credible evidence.

Premium or trial research capacity should be spent on questions that cannot be answered efficiently through public primary sources or direct buyer validation.

## MAP Boundary Hold

The operative Project Source Authority Index preserves an unresolved MAP terminology conflict among previously used formulations, including `Measure-Audit-Prepare`, `MAP the Environment`, and `Measure-Align-Prepare`.

This ledger does not resolve that terminology.

GTM research may later be mapped relationally to MAP only after the applicable MAP terminology and relationship receive their own governed resolution.

Standing:

`HELD — MAP terminology and GTM↔MAP canonical relation unresolved`

## Custody and Registry Relation

Current formation establishes Git custody only.

Proposed long-term relation:

- Git preserves authoritative versioned document custody.
- Measures Registry may record stable artifact identity, version, standing, SHA-256, authoritative custody location, and applicable relationships.
- Research records may accumulate as append-only evidence or versioned ledger updates.
- Registration does not make every research finding operative.
- Publication, activation, sales execution, database mutation, or MAP resolution requires its own applicable authority.

## Change Rule

Material changes to the five-gate architecture, healthcare case standing, canonical offer identity, market disposition, MAP relation, or registry standing require review and Operator disposition.

New evidence may be appended without rewriting historical findings. Corrections should preserve prior evidence and state the corrected condition.

## Formation Standing

This v1 artifact is formed in Git under direct Operator authorization for Git construction.

It is pending Chazz return review and Operator disposition for merge and any later Registry registration.

No Registry mutation, public publication, sales activation, contact enrichment, outreach enrollment, deployment, or MAP terminology resolution is authorized by this formation.
